$1.31
0.77% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US7574681034
Symbol
RDHL

RedHill Biopharma Ltd. Sponsored ADR Stock price

$1.31
-0.86 39.63% 1M
-3.51 72.82% 6M
-4.90 78.91% YTD
-8.22 86.25% 1Y
-930.19 99.86% 3Y
-7,558.69 99.98% 5Y
-12,158.69 99.99% 10Y
-11,098.69 99.99% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 0.77%
ISIN
US7574681034
Symbol
RDHL
Industry

Key metrics

Basic
Market capitalization
$3.0m
Enterprise Value
$-1.3m
Net debt
positive
Cash
$4.6m
Shares outstanding
12.9b
Valuation (TTM | estimate)
P/E
- | -
P/S
0.3 | 0.1
EV/Sales
negative | negative
EV/FCF
0.1
P/B
negative
Financial Health
Equity Ratio
-26.0%
Return on Equity
176.6%
ROCE
551.7%
ROIC
-
Debt/Equity
-0.1
Financials (TTM | estimate)
Revenue
$10.6m | $38.8m
EBITDA
$-22.4m | -
EBIT
$-23.1m | $-6.6m
Net Income
$-11.4m | -
Free Cash Flow
$-9.4m
Growth (TTM | estimate)
Revenue
-11.0% | 382.1%
EBITDA
-157.1% | -
EBIT
-161.8% | 54.6%
Net Income
-115.2% | -
Free Cash Flow
73.8%
Margin (TTM | estimate)
Gross
56.7%
EBITDA
-211.4% | -
EBIT
-217.3%
Net
-107.0% | -
Free Cash Flow
-88.4%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
5.2%
Employees
35
Rev per Employee
$230.0k
Show more

Is RedHill Biopharma Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
11% 11%
100%
- Direct Costs 4.60 4.60
22% 22%
43%
6.02 6.02
0% 0%
57%
- Selling and Administrative Expenses 24 24
51% 51%
230%
- Research and Development Expense 2.25 2.25
62% 62%
21%
-22 -22
157% 157%
-211%
- Depreciation and Amortization 0.62 0.62
69% 69%
6%
EBIT (Operating Income) EBIT -23 -23
162% 162%
-217%
Net Profit -11 -11
115% 115%
-107%

In millions USD.

Don't miss a Thing! We will send you all news about RedHill Biopharma Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral
PRNewsWire
4 days ago
The New York Supreme Court has awarded RedHill approximately $1.82 million in legal costs and expenses following, and in addition to, the Court's prior summary judgment of approximately $8.25 million in favor of RedHill in its action against Kukbo Co. Ltd's ("Kukbo"); the $8.25 million and $1.82 million awards include 9% ongoing statutory interest accrual RALEIGH, N.C. and TEL-AVIV, Israel , Au...
Neutral
PRNewsWire
6 days ago
RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S. commercial launch of Talicia in 2024 Talicia is the first FDA-approved rifabutin-based product specifically designed to treat Helicobacter pylori (H. pylori), a bacterial infection with high and rising resistance rates that affects over 50% o...
Neutral
PRNewsWire
about one month ago
The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) patient population Groundbreaking approach testing MAP as a root cause of CD, supporting RHB-204 as a potential paradigm-shifting therapy treating both the suspec...
More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Dror Ben-Asher
Employees 35
Founded 2009
Website www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today